According to reports, Takeda Pharmaceutical is looking to buy Swiss pharma company Nycomed, which manufactures several OINDPs, including the Alvesco ciclesonide MDI and Omnaris ciclesonide nasal spray. Nycomed is also developing a ciclesonide HFA nasal aerosol in partnership with Sunovion (formerly Sepracor); that product is currently in Phase 3.
Takeda is reportedly offering approximately $12-14 billion for Nycomed, which is currently privately owned. The deal would be the second largest acquisition of a foreign company by a Japanese business.
Nycomed employs 12,500 people and has 5 manufacturing facilities in Europe and 10 in other regions. The company also has 3 R&D centers in Europe and 1 in India.
Read the Reuters report.
Read the Wall Street Journal report.
